Xen63 Ab Externo: Preliminary Analysis Of Safety And Efficacy In A Series Of Cases
Published 2024 - 42nd Congress of the ESCRS
Reference: PO1070 | Type: Free paper | DOI: 10.82333/f007-3a94
Authors: Yann Bertolani* 1 , Jaume Rigo 1 , Marta Castany 1 , Tetiana Goncharova 1 , Antoni Dou Saenz de Vizmanos 1 , Olivia Pujol 1 , Manuel Amilburu 1
1Ophtalmology,Hospital Vall d'Hebron,Barcelona,Spain
Purpose
To study the safety and efficacy of the novel XEN®63 Gel Stent (Allergan Inc., CA, USA) with the ab externo approach in a series of patients.
Setting
The diagnosis, surgical indication, surgical procedure and postoperative follow-up were carried out by glaucoma specialist at the Vall d'Hebron University Hospital, Barcelona, Spain.
Methods
A retrospective analysis of XEN63 implants from November 2022 to July 2023 was performed. The XEN63 were implanted via an ab externo approach both with injector or with the 30G needle technique. Primary objectives were mean intraocular pressure (IOP) at 3,6 and 12 months after surgery and postoperative complications, including hypotonic maculopathy and choroidal detachment.
Results
17 XEN63 using an ab externo approach were included. 2 were performed with injector and 15 were inserted through a scleral traject with 30G needle. Primary open angle glaucoma (POAG) accounted for 58,8% of cases. Mean preoperative IOP was 24.1±8.2 mmHg. Mean follow up time was 344,5 days. Mean postoperative IOP was 12.6±7.8, 13.2±4.8 and 11.9±3.0 mmHg at 3,6 and 12 months. Thus, XEN63 showed significative IOP reduction at 3, 6 and 12 months. Interestingly, there were 3 cases of choroidal detachment occurring three weeks after the surgery, one of which required injection of viscoelastic in anterior chamber. Moreover, one case underwent a second surgery due to a dellen caused by bleb dysesthesia with favorable outcome.
Conclusions
The novel XEN 63 implant offers an effective reduction of IOP at short and medium term. Interestingly, there are no other series of cases published in the literature concerning the ab externo approach for this device. However, it is crucial to extend the follow-up to confirm the long-term efficacy of the implant. It is important to highlight cases of choroidal detachments associated with hypotony, likely related to the increased diameter of the device. Thus, there are no previous described cases of choroidal detachment in XEN63 ab externo.